In liver cancer, durvalumab and bevacizumab added to TACE are beneficial.

Published Date: 31 Jan 2024

Durvalumab (D) and bevacizumab (B) added to transarterial chemoembolization (TACE) improves progression-free survival (PFS) for patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot